DR-238 Accurate Discrimination of Major Cancer Types via Whole Genome Somatic Mutation Patterns
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-238 Accurate Discrimination of Major Cancer Types via Whole Genome Somatic Mutation Patterns
The two strongest factors predicting a human cancer’s clinical behaviour are the primary tumour’s anatomic organ of origin and its …
DR-232 Whole Genome Sequencing can classify diagnostically challenging tumors.
Cancer of Unknown Primary (CUP) accounts for approximately 3% of all metastatic cancers. Despite modern imaging techniques and extensive pathology …
DR-229 identifying patients that are resistant to EGFR-targeting therapy
EGFR-targeting therapies are used as anti-cancer agents. Not all patients respond well and side-effects can be significant. Therefore, biomarkers that …
DR-228 Artificial intelligence based predictive model for response to Immune Checkpoint inhibitors based on multiplex immunohistochemistry and whole genome analysis (ARCTIC)
Immunotherapy, like nivolumab and pembrolizumab, has drastically improved the survival of many cancer patients. However, some patients do not clinically …
DR-227 ctDNA analysis to monitor response to neoadjuvant chemoradiation in esohageal cancer patients
PurposeAfter treatment with a combination of chemotherapy and radiotherapy for esophageal cancer, the current standard treatment is to continue with …
DR-225 Comprehensive molecular characterization of mitochondrial genomes in human metastatic cancers
Cancer is a deadly disease affecting millions of people worldwide. Tumor metastasis is the most frequent cause of death. The …
DR-222 Microbiome in metastatic cancer
In this study we will investigate the microbiome in metastatic cancer. We will use whole genome sequencing data from solid …
DR-221 Multi-omics profiling of tumors
Cancer is caused by mutations in the DNA, which can be analyzed by sequencing the tumor’s DNA. We can observe …
DR-220 An exploratory study on genomic correlates of anti-tumour immunity in castration-resistant prostate cancer.
Checkpoint inhibitors have failed to demonstrate a survival benefit in unselected castration-resistant prostate cancer (CRPC) patients. Nevertheless, biochemical and radiographic …
DR-219 Colorectal cancer (CRC) predisposition
We will use whole genome sequencing data derived from blood or normal tissue of colorectal cancer (CRC) patients in a …
DR-216 Uncovering the landscape of MHC peptides derived from low translation fidelity and their their impact on anti-cancer immunity
The purpose of the project is to search for repeating mutations in genes related to translation in cancer. Such genes …
DR-213 Copy number changes, DNA repair mechanisms and cisplatin resistance in germ cell tumors
We observed specific chromosomal copy number changes in germ cell tumors that are proven to be resistant to cisplatin-based chemotherapy. …
Zolang de behandelaar niet weet waar de primaire tumor zit, heeft hij ook geen gerichte behandelmogelijkheid en kan ook geen inschatting worden gegeven hoe lang iemand nog heeft.